Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (ACTRN12625000924459) titled 'EMPRESS Trial: Assessing the efficacy of EMPagliflozin in REducing Coronary Stent ReStenosis Rates in Type 2 Diabetes' on Aug. 25.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Open (masking not used)
Assignment: Parallel
Type of endpoint: Efficacy
Primary Sponsor: Northern Health
Condition:
Type 2 Diabetes Mellitus
Ischaemic Heart Disease
Type 2 Diabetes Mellitus
Ischaemic Heart Disease
Cardiovascular - Coronary heart disease
Metabolic and Endocrine - Diabetes
Intervention:
Empagliflozin orally at 10mg daily for nine months.
Empagliflozin ...